Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Effectiveness trials: critical data to help understand how respiratory medicines really work?
GSK, GSK Nord Cluster, Solna, Sweden.
Orebro Univ, Dept Resp Med, Sch Med Sci, Orebro, Sweden.
Lund Univ, Dept Clin Sci Lund Resp Med & Allergol, Lund, Sweden.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Lung- allergy- and sleep research.ORCID iD: 0000-0001-5093-6980
2019 (English)In: European Clinical Respiratory Journal, ISSN 2001-8525, Vol. 6, no 1, article id 1565804Article, review/survey (Refereed) Published
Abstract [en]

Most of the information about the benefits, safety aspects, and cost effectiveness of pharmacological treatment in the respiratory field has been obtained from traditional efficacy studies, such as randomised controlled trials (RCT). The highly controlled environment of an RCT does not always reflect everyday practice. The collection, analysis, and application of effectiveness data to generate Real World Evidence (RWE) through pragmatic trials or observational studies therefore has the potential to improve decision making by regulators, payers, and clinicians. Despite calls for more RWE, effectiveness data are not widely used in decision making in the respiratory field. Recent advances in data capture, curation, and storage combined with new analytical tools have now made it feasible for effectiveness data to become routine sources of evidence to supplement traditional efficacy data. In this paper, we will examine some of the current data gaps, diverse types of effectiveness data, look at proposed frameworks for the positioning of effectiveness data, as well as provide examples from therapeutic areas. We will give examples of both previous effectiveness studies and studies that are ongoing within the respiratory field. Effectiveness data hold the potential to address several evidentiary gaps related to the effectiveness, safety, and value of treatments in patients with respiratory diseases.

Place, publisher, year, edition, pages
TAYLOR & FRANCIS LTD , 2019. Vol. 6, no 1, article id 1565804
Keywords [en]
Effectiveness, real-world evidence, pragmatic trials, evidence-base, efficacy RCT, levels of evidence, respiratory disease, asthma, COPD, co-morbidity
National Category
Respiratory Medicine and Allergy
Identifiers
URN: urn:nbn:se:uu:diva-377497DOI: 10.1080/20018525.2019.1565804ISI: 000457088000001PubMedID: 30728925OAI: oai:DiVA.org:uu-377497DiVA, id: diva2:1291052
Available from: 2019-02-22 Created: 2019-02-22 Last updated: 2019-02-22Bibliographically approved

Open Access in DiVA

fulltext(975 kB)57 downloads
File information
File name FULLTEXT01.pdfFile size 975 kBChecksum SHA-512
8cd0b5b458774e16f44cd00cbf0930fb4d1c1b7e0caaed1e1de9489f6d1fcd401b4850a35a2993d85dca1b9ac632828fe6cc534fe2083e3ee87374173e0290c6
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Janson, Christer
By organisation
Lung- allergy- and sleep research
In the same journal
European Clinical Respiratory Journal
Respiratory Medicine and Allergy

Search outside of DiVA

GoogleGoogle Scholar
Total: 57 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 85 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf